GLP-1 Initiation Did Not Improve Insulin Discontinuation Rates Among Veterans with Type 2 Diabetes
A target trial emulation found that adding glucagon-like peptide-1 receptor agonists (GLP-1RAs) to basal insulin therapy for type 2 diabetes did not increase the likelihood of stopping insulin…
Read the full articleYou might also wanna read
Study Dampens Hope for GLP-1s as Insulin Off-Ramp in Type 2 Diabetes
(MedPage Today) -- Adding a GLP-1 receptor agonist was not associated with a lower likelihood of discontinuing existing basal insulin therap
Can GLP-1 medications improve health in people with Type 2 diabetes and PAD?
Research Highlights: GLP-1RA (glucagon-like peptide-1 receptor agonist) medications, which are prescribed to treat Type 2 diabetes and to he
GLP-1 vs SGLT2: The New Frontier in Diabetes Therapy
A new commentary in The Lancet examines whether oral GLP-1 receptor agonists can match SGLT2 inhibitors in cardiovascular and kidney protect
EFL033 - GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes
Join host Chase Hendrickson, MD, from Vanderbilt University Medical Center as he discusses an article in The Journal of Clinical Endocrinolo
GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation
Conditions : Alzheimer Disease; Diabetes Mellitus Type 2; Obesity & Overweight Interventions : Drug: GLP-1 Receptor Agonists; Drug: DPP-4 In
Comments
Sign in to join the conversation.
No comments yet. Be the first.